<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244166</url>
  </required_header>
  <id_info>
    <org_study_id>P-01</org_study_id>
    <nct_id>NCT00244166</nct_id>
  </id_info>
  <brief_title>Prednisolone in Active Ankylosing Spondylitis (AS)</brief_title>
  <official_title>Threecenter Placebo Controlled Three Arm Trial in Patients With Active Ankylosing Spondylitis With Prednisolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      1. to investigate whether steroids are effective in ankylosing spondylitis&#xD;
&#xD;
        2. if steroids are effective to describe how quick they work&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of inflammatory rheumatic conditions with glucocorticosteroids is a mainstay in&#xD;
      therapy. In rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematodes and&#xD;
      polymyalgia rheumatica glucocorticosteroids show a prompt effect in regards of&#xD;
      musculoskeletal symptoms.&#xD;
&#xD;
      Ankylosing spondylitis (AS) is an inflammatory rheumatic disease mainly affecting the spine.&#xD;
      However peripheral joints, entheses and the eyes can also be affected. The rheumatic symptoms&#xD;
      of AS patients typically show good and quick response to treatment with nonsteroidal&#xD;
      antirheumatic drugs (NSAIDs). In contrast to rheumatoid arthritis there is no proof that&#xD;
      disease modifying antirheumatic drugs (DMARDs) work. Surprisingly there is the common&#xD;
      opinion, mainly based on personal experiences, that glucocorticosteroids in&#xD;
      spondylarthropathies do not work. However there are no reliable clinical studies answering&#xD;
      this question. In the literature of the last 20 years there are only single reports about the&#xD;
      treatment of AS with highly dosed methylprednisolone (intravenous pulse therapy). The&#xD;
      pretended lack of effectiveness of glucocorticosteroids surprises moreover as NSAIDs are very&#xD;
      effective as well as local intraarticular steroid injections including the sacroiliac joints.&#xD;
      In addition with magnetic resonance imaging acute inflammatory lesions can be visualized&#xD;
      especially as subchondral edema in bone marrow. Besides about 70% of patients with active AS&#xD;
      show elevated inflammatory serum markers such as erythrocyte sedimentation rate (ESR) and&#xD;
      C-reactive protein (CRP). Moreover we could recently that a treatment of AS patients with the&#xD;
      monoclonal antibody against TNFa (Infliximab) is highly effective. TNFa is a very important&#xD;
      pro-inflammatory cytokine (Brandt et al 2000).&#xD;
&#xD;
      For all these reasons it is very important and urgent to perform a study for the treatment of&#xD;
      active AS with glucocorticosteroids using evaluated measuring instruments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2002</start_date>
  <completion_date>August 2008</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>50% improvement of BASDAI after 14 days of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of pain on a VAS 0 - 10</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of CRP/ BSG</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of swollen/tender joints</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of enthesitic localisations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of function (BASFI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement of quality of life (SF12)</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ankylosing spondylitis according to the modified NY criteria 1984&#xD;
&#xD;
          2. age between 18 and 70 years&#xD;
&#xD;
          3. insufficient response to therapy with NSAIDs&#xD;
&#xD;
          4. BASDAI &gt; 4&#xD;
&#xD;
          5. Previous therapy with DMARDs (such as sulfasalazine, methotrexate etc.) or steroids&#xD;
             less than or equal to 7,5mg is allowed, should be discontinued or stable 4 weeks&#xD;
             before study start&#xD;
&#xD;
          6. written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. current severe infection or during the last 3 months&#xD;
&#xD;
          3. suspected opportunistic infection during the past 2 months (such as Herpes zoster,&#xD;
             cytomegaly-, Pneumocystis carinii-infection), HIV-infection&#xD;
&#xD;
          4. Malignancies&#xD;
&#xD;
          5. severe cardial, renal, hematological, endocrinological, pulmonal, gastrointestinal&#xD;
             (such as peptic ulcers) neurological, hepatic (viral or toxic hepatitis) concomitant&#xD;
             disease, uncontrolled arterial hypertension remitting thrombosis, embolism&#xD;
&#xD;
          6. Diabetes mellitus or increased blood glucose test&#xD;
&#xD;
          7. uncontrolled glaucoma&#xD;
&#xD;
          8. active immunization during the past 2 weeks or planned for the next 8 weeks&#xD;
&#xD;
          9. pathologic laboratory test results: creatinine &gt;200 µmol/l, liver enzymes &gt; 2,5 fold,&#xD;
             AP &gt;2,5 fold upper normal ranges&#xD;
&#xD;
         10. significant pathological changes during physical examination&#xD;
&#xD;
         11. clinical trial participation during the past 30 days before screening&#xD;
&#xD;
         12. intake of &quot;hard drugs&quot; (such as cocaine, heroin)&#xD;
&#xD;
         13. therapy with more than 7,5 mg prednisolone, intraarticular steroids during the past 4&#xD;
             weeks before study start&#xD;
&#xD;
         14. current application for retirement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Sieper, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Campus Benjamin-Franklin Rheumatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joachim Sieper, Prof.</last_name>
    <phone>0049 30 8445</phone>
    <phone_ext>4414</phone_ext>
    <email>joachim.sieper@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hildrun Haibel, MD</last_name>
    <phone>0049 30 8445</phone>
    <phone_ext>4414</phone_ext>
    <email>hildrun.haibel@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Campus Benjamin-Franklin Rheumatolgy</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Sieper, Prof.</last_name>
      <phone>0049 30 8445</phone>
      <phone_ext>4414</phone_ext>
      <email>joachim.sieper@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Hildrun Haibel, MD</last_name>
      <phone>0049 30 8445</phone>
      <phone_ext>4414</phone_ext>
      <email>hildrun.haibel@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Joachim Sieper, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hildrun Haibel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henning C Brandt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>In-Ho Song, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immanuel Hospital Rheumatology</name>
      <address>
        <city>Berlin</city>
        <zip>14109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Krause, Prof.</last_name>
      <phone>0049 30 80505</phone>
      <phone_ext>293</phone_ext>
      <email>a.krause@immanuel.de</email>
    </contact>
    <investigator>
      <last_name>Andreas Krause, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen Braun, Prof.</last_name>
      <phone>0049 2325592</phone>
      <phone_ext>131</phone_ext>
      <email>j.braun@rheumazentrum-ruhrgebiet.de</email>
    </contact>
    <contact_backup>
      <last_name>Xenofon Baraliakos, MD</last_name>
      <phone>0049 2325592</phone>
      <phone_ext>131</phone_ext>
      <email>xenob@onlinehome.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen Braun, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xenofon Baraliakos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2006</last_update_posted>
  <keyword>treatment</keyword>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>prednisolone</keyword>
  <keyword>trial</keyword>
  <keyword>steroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

